GSA Capital Partners LLP lessened its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 18.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 316,900 shares of the biopharmaceutical company’s stock after selling 70,358 shares during the period. GSA Capital Partners LLP owned approximately 0.23% of Achillion Pharmaceuticals worth $1,423,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. RTW Investments LP lifted its position in shares of Achillion Pharmaceuticals by 392.9% during the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock worth $35,201,000 after purchasing an additional 6,249,312 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Achillion Pharmaceuticals during the 2nd quarter worth $20,778,000. Dimensional Fund Advisors LP raised its stake in Achillion Pharmaceuticals by 75.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock worth $14,710,000 after acquiring an additional 1,407,108 shares in the last quarter. Sarissa Capital Management LP acquired a new stake in Achillion Pharmaceuticals during the 3rd quarter worth $9,594,000. Finally, FMR LLC raised its stake in Achillion Pharmaceuticals by 11.0% during the 2nd quarter. FMR LLC now owns 1,603,622 shares of the biopharmaceutical company’s stock worth $7,361,000 after acquiring an additional 159,218 shares in the last quarter. 76.92% of the stock is owned by institutional investors.
In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.24% of the company’s stock.
Several equities research analysts recently commented on the stock. Chardan Capital reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Leerink Swann restated a “buy” rating and issued a $5.00 price objective on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. Finally, BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, December 21st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. Achillion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $5.13.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) traded up $0.02 during midday trading on Thursday, hitting $2.99. 1,235,318 shares of the company’s stock traded hands, compared to its average volume of 1,943,265. Achillion Pharmaceuticals, Inc. has a 12 month low of $2.69 and a 12 month high of $5.66. The stock has a market capitalization of $412.19, a P/E ratio of -6.10 and a beta of 1.52.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. During the same quarter last year, the business posted ($0.15) earnings per share. analysts predict that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “GSA Capital Partners LLP Has $1.42 Million Stake in Achillion Pharmaceuticals, Inc. (ACHN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/gsa-capital-partners-llp-has-1-42-million-stake-in-achillion-pharmaceuticals-inc-achn.html.
Achillion Pharmaceuticals Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.